Author:
Rosenberg Jacqueline Gremaud,Nissen Kamilla,Heegaard Steffen,Ragunathan Suganiah,Schmiegelow Kjeld,Mathiasen René,von Holstein Sarah Linea
Abstract
Abstract
Background
The aim of the study was to evaluate the prevalence, clinical characteristics, and diagnostic importance of nystagmus in children with brain tumours.
Methods
A nation-wide retrospective review of all children diagnosed with a brain tumour between January the 1st, 2007 and December 31st, 2017, in Denmark. Data is based on information from the Danish Childhood Cancer Registry, hospital records from paediatric- and ophthalmological departments, and records from private ophthalmologists.
Results
Nystagmus was observed in 13.7% (60/437) of children with a brain tumour. In 50/60 children (83.3%) nystagmus was an incidental finding at the clinical examination and only in 10/60 children (16,7%) were nystagmus noticed by patient/caregivers prior to the clinical examination. In 38/60 children nystagmus was observed before the brain tumour diagnosis, most often (16/38, 42%) the same day as the diagnosis was made. In 22/60 children nystagmus was found after the brain tumour diagnosis (prior to any treatment) with a median of four days (range 0-47) after the brain tumour diagnosis. Nystagmus was most commonly binocular (56/60, 93.3%) and gaze-evoked (43/60, 71.7%). The median number of additional symptoms and/or clinical findings was five (range 0–11).
Conclusion
Nystagmus is frequent in children with brain tumours and is typically accompanied by other symptoms and clinical signs. However, nystagmus is often first recognized by the ophthalmologist late in the time course. Therefore, raising awareness of the importance of looking for nystagmus in children with unspecific neurological symptoms might contribute to increased suspicion of brain tumour and thereby faster diagnosis.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Kyu HH, Stein CE, Boschi Pinto C, Rakovac I, Weber MW, Purnat TD, et al. Causes of death among children aged 5–14 years in the WHO European Region: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Child Adolesc Heal. 2018;2:321–37.
2. Macedoni-Lukšič M, Jereb B, Todorovski L. Long-term sequelae in children treated for brain tumors: Impairments, disability, and handicap. Pediatr Hematol Oncol. 2003;20:89–101.
3. Walker D, Grundy R, Kennedy C, Collier J, Wilne S, Koller K. The Brain Pathways Guideline: A Guideline To Assist Healthcare Professionals in the Assessment of Children Who May Have a Brain Tumour. 2017;2017:0–127. www.nice.org.uk/accreditation.
4. Wilne SH, Ferris RC, Nathwani A, Kennedy CR. The presenting features of brain tumours: A review of 200 cases. Arch Dis Child. 2006;91:502–6.
5. Ahrensberg JM, Schrøder H, Hansen RP, Olesen F, Vedsted P. The initial cancer pathway for children - One-fourth wait more than 3 months. Acta Paediatr Int J Paediatr. 2012;101:655–62.